Introduction
Cisplatin (CDDP) treatment is the first-line chemotherapy drug used in patients affected by various types of tumors, including metastatic testicular and ovarian tumors. Testicular germ cell tumors (TGTs) are the main cause of cancer in men between 15 and 35 years of age (1) . These tumors have excellent cure rates, with more than 90% of patients achieving a complete response to CDDP-based treatment, either alone or combined with surgery.
Metastatic TGT has the highest cure rate, with a survival rate of 80%. However, a proportion of patients relapse or develop refractory diseases following CDDP treatment. For these patients, any new treatment would be considered an alternative treatment and, therefore, poor prognosis is often the result (2).
Resistance to chemotherapy is one of the major causes of death in cancer patients. The cellular mechanisms for CDDP resistance involve a decrease in drug uptake or an increase in its expulsion from tumor cells, CDDP inactivation due to binding to sulfur-rich proteins, alterations in the capacity of DNA repair or a lack of detection of DNA damage, and a failure to enter cell death after DNA damage (3) (4) (5) . The latter mechanism may result from different alterations in tumors, including induction of anti-apoptotic factors or decrease in pro-apoptotic factors, but it may also be due to alterations in signal transduction pathways that normally regulate apoptosis, survival and proliferation (5) .
Therefore, tumors that present wild-type p53, a key protein for inducing apoptosis after DNA damage, respond well to CDDP compared with those tumors that present p53-inactivating mutations. This is seen in TGTs that are particularly sensitive to CDDP, since they are one of the few cancers in which p53 is rarely inactivated (6) . Activation of p38 MAPK, a kinase involved in apoptosis induction, is also altered in CDDP-resistant lung cells (7, 8) . Prosurvival signals, such as PI3K-AKT or ERKs, are overstimulated in some CDDP-resistant cells, such as lung or ovarian cell lines (3) . However, Fung et al described that blocking MEK/ERK led to cellular protection against CDDPinduced apoptosis in TGT cell lines (9) . Our study examines the possible contribution of some of these signaling pathways to the acquisition of CDDP resistance in human testicular tumor cells.
Research. kindly provided by AstraZeneca, Ly2109761 was kindly provided by Eli Lilly, and Ly294002 and UO126 were obtained from Calbiochem. All the above compounds were dissolved in DMSO. CDDP was provided by Pfizer and was diluted in sterile serum. PDGF-BB and FGF-2 were provided by R&D, and EGF was provided by Sigma.
Cell culture
The human teratocarcinoma cell line SuSa, or SuSaS ("S" for sensitive to CDDP) (10), and GCT27, or GCT27S cells (from embryonic carcinoma origin) ) supplemented with 20% FCS, while GCT27 cells were cultivated in DMEM medium (Gibco ® ) supplemented with 10% FCS. 50 U/ml penicillin, 50 µg/ml streptomycin sulfate and 2 mM glutamine were added to all cell culture media.
All cells were grown at 37ºC in a humidified atmosphere with 5% CO 2 .
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Tumor samples
We used two orthotopic testicular GCTs models for our studies: a choriocarcinoma (TGT38) and its cisplatin-resistant counterpart (TGT38R), both of which have been described in Castillo-Avila et al (14) . All animal studies were approved by the local committee (IDIBELL) for animal care. As these vectors express puromycin resistance, cell lines expressing lentiviral vectors were established in constant culture of puromycin-containing media (2 µg/ml). To confirm the correct PDGFRβ silencing by lentiviral vectors, protein samples from the cell lines were collected and processed in a western blot.
Cell viability assay
Cell viability was determined by measuring the metabolic activity using the methyl-thiazole-tetrazolium (MTT) assay (Sigma Chemical). Cells were mg/ml of CDDP for 4 days. DMSO was used as a negative control when a different drug was added to the CDDP dose curve in the GCT27S or R cells.
When appropriate, a constant dose of pazopanib (0.5 µg/ml) or Ly294002 (4 µM) was added. Subsequently, when treatment was finished, 10 µM MTT was added to each well and incubated for an additional 4 hours. The blue MTT formazan precipitate was dissolved in DMSO and the optical density was measured (absorbance at 570 nm) on a multiwell plate reader. The pazopanib (0-10 µg/ml) curve was measured in the same manner.
Western blot
Samples from cells or tumors were lysed using RIPA lysis buffer. Protein lysates were processed as previously described (14) . Antibodies used in this study are described in the Supplementary Material section.
Elisa
Human PDGF-BB protein levels were measured using an Elisa Kit from RayBio, following the manufacturer's instructions. When appropriate, PDGF-BB was quantified on cell-cultured media without FBS for 16 h. The intensity of PDGFRβ stain was scored using a grading scale, defined as follows: no detectable signal (0 points), low-intensity signal (1 point), moderate-intensity signal (2 points), or high-intensity signal (3 points). Labeling frequency was scored as the percentage of positive tumoral cells. The multiplicative index of intensity and labeling frequency was used in our analysis, as previously described (15) .
Statistical analyses
Statistical analysis was carried out using SPSS (SPSS for Windows 13.0, SPSS, Inc., Chicago, IL). Statistical significance of differences between groups was determined using the Mann-Whitney U test, statistical significance being concluded for values of p < 0.05 (*) or p<0.01 (**) relative to the GCT27S value in all experiments. Dose-response curves and IC 50 statistics were generated using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA)..
Results
To explore the mechanisms involved in CDDP resistance in depth, we (Fig. 2C) . In contrast, no effect of ErbBs or TGFβ inhibitors was observed in these cells. We also observed a slight decrease in ERK1/2 activity with both cells, we found a 4-fold increase in total levels (Fig. 3B) , and an increase in the amount of PDGFRβ in the plasmatic membrane ( Supplementary Fig. 1 ).
However, no differences were observed in PDGFRα protein levels (Fig. 3B) . We also measured mRNA and protein levels for the PDGFRs ligands PDGF-A and PDGF-B. As shown in Fig. 3C , mRNA levels for this latter growth factor were 6.5-fold those in resistant cells, while no significant differences were detected for the PDGF-A growth factor. Protein PDGF-B levels measured by Elisa were also higher in cell lysates (2.9-fold) and cell-culture media (6.9-fold) for resistant
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compared with cisplatin-sensitive cells (Fig. 3D) . Similar results were obtained in SuSa cells (Supplementary Fig. 2 ). Together, these results indicate that CDDP-resistance in testicular tumor cells was associated with an increase in the activation of the PDGF-B/ PDGFRβ/PI3K-AKT pathway.
To confirm that AKT activation by PDGFRβ caused CDDP resistance by modifying the potential viability of these cells, we evaluated the effect of the PDGFR inhibitor pazopanib (0.5 µg/ml) on the CDDP dose-response curve.
Pazopanib treatment in normal GCT27 cells did not significantly affect the CDDP IC 50 (Fig. 4A) . In contrast, when pazopanib was added to CDDPresistant cells, they recovered sensitivity to CDDP, and an IC 50 value similar to sensitive cells was noted (7.2·10 -4 mg/ml SD 3.4·10 -4 for GCT27R, 2.81·10 PDGFRs by pazopanib treatment reverted GCT27 cells to CDDP sensitivity.
Next, to assess whether PDGFRβ was sufficient to explain CDDPresistance, we inhibited its expression in GCT27R cells. By transducing lentiviral vectors expressing either PDGFRβ-shRNAs or a negative control using an empty vector (EV), GCT27R-EV cells as controls or GCT27R-shPβ cells were generated. We used four independent shRNA vectors but only one of them (shPβ4) partially reduced PDGFRβ expression protein without having effects on PDGFRα (Fig. 4B ). This partial blocking of PDGFRβ expression also partially blocked phosphoAKT levels (Fig. 4B ). As shown in Fig. 4C , decreased
Research. PDGFRβ levels in GCT27R-shPβ4 cells caused a partial recovery in CDDP sensitivity, indicating that inhibition of this receptor affected CDDP resistance.
Although the difference in IC 50 values between GCT27R and GCT27R-shPβ4
was not statistically significant, we observed a significant decrease in the sensitivity of GCT27R-shPβ4 compared with the resistant cell line when 10 -4 mg/ml CDDP was used. Moreover, at this CDDP concentration, the sensitivity of these three cell lines to the drug was linearly proportional to the phosphoAKT levels detected by western blot (Fig. 4B and Supplementary Fig. 3 ).
We also analyzed PDGF-dependence in CDDP-resistant cells compared with normal cells. To this end, we treated GCT27S or R cells with a range of concentrations of PDGFR inhibitors (pazopanib, Fig. 4D , or sunitinib, data not shown), then studied cell viability. We observed that CDDP-resistant cells were more sensitive to these inhibitors, with levels of cell viability inhibition around 90%, compared with 70% in normal cells (Fig. 4D) . These results indicated that overexpression of PDGF-B and PDGFRβ in CDDP-resistant cells increases the degree of addiction of these cells to follow this pathway.
To determine whether these in vitro associations between acquiredcisplatin resistance and activation of the PDGFR pathway were also present in tumors, we analyzed PDGFR expression in an orthotopic model of testicular germ cell choriocarcinoma tumor (TGT38) and its CDDP-resistant counterpart (TGT38R). These resistant tumors were generated in our laboratory using a mouse model bearing a TGT38 tumor subjected to prolonged CDDP treatment (14) . We did not detect differences in mRNA or protein levels for the PDGFRs ligand PDGF-B in this model ( Supplementary Fig. 4 ). mRNA levels for PDGFRα were found to be equal in TGT38 and TGT38R tumors (Fig. 5A) . In contrast, a 2.2-fold increase in PDGFRβ mRNA levels was found in resistant tumors relative to the CDDP sensitive tumors. This result was confirmed by western blot analysis of PDGFRβ protein levels. Additionally, a 3-fold increase in PDGFRβ expression levels was observed in the CDDP-resistant tumor along with a 2-fold increase in pAKT levels (Fig. 5B) , confirming the relevance of the activation of the PDGFRβ-pAKT pathway in conferring cisplatin resistance. resistant choriocarcinomas had a higher index than sensitive choriocarcinomas, and a significantly higher index than those untreated patients (Fig. 5D ).
Discussion
This study has shown that an increase in activity of the PDGFRβ-AKT CDDP pathway is a hitherto unidentified mechanism of CDDP resistance in testicular cancer cells. Activation of PI3K as a mechanism of CDDP resistance has been previously described. For example, the increased activation of pAKT in human lung tumor tissues is inversely correlated with CDDP sensitivity in their primary derived culture counterpart (16). Moreover, a high level of PI3K activity in NSCLC CDDP-resistant patients through overexpression of ErbB2 receptor (17) , or through EGFR/Her3 in glioma and ovarian cancer cells has also been described (18) . Another mechanism involved in cisplatin resistance is the downregulation of PTEN by induction of microRNAs, such as miR-214 (19) and miR-93 (20) 
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carcinoma cells resistant to paclitaxel (26) . However, to our knowledge, this is one of the first times that not only an autocrine PDGF loop, but also regulation of PDGFR expression have been implicated in CDDP resistance. The molecular mechanisms contributing to this response require further investigation. We did not detect any differences in the methylation of the PDGFRβ promoter (data not shown), a classic mechanism known to induce or repress gene expression.
Neither were there any differences in the regulation of PDGF-BB-PDGFRβ-pAKT activation by the TGFβ pathway (Fig. 2) , as described in glioma models (27) . Nevertheless, other mechanisms could be involved, such as microRNA regulation or transcription factor activity. All of these mechanisms are regulated by CDDP in various tumor cell types (15, 28) .
Our results indicate that sensitivity to CDDP depends on the phosphoAKT levels in the cells. In fact, in testicular tumor cells, we observed a perfect correlation between phosphoAKT levels and cell viability upon CDDP treatment ( Supplementary Fig. 3 ). Moreover, resistant cells recovered their sensitivity to CDDP when levels of phosphoAKT were reduced by Ly294002. 
